Insights

Innovative Technology Adoption International Stem Cell Corporation specializes in advanced stem cell technology called parthenogenesis, which offers significant therapeutic potential and addresses immune rejection challenges. This groundbreaking approach presents opportunities to collaborate on developing immune-compatible cell therapies, potentially expanding sales in regenerative medicine.

Growing Market Expansion With plans to establish a universal stem cell bank (UniStemCell) capable of serving diverse populations globally, there are opportunities to provide specialized cell bank services, licensing, and related biorepository solutions to meet expanding demand in personalized medicine and cellular therapies.

Product and Service Diversification The company's operations include Lifeline Cell Technology and Lifeline Skin Care, indicating multiple avenues for cross-selling and expanding into specialty cell products, skin care ingredients, and related research tools to target biotech and dermatology markets.

Funding and Revenue Potential With a revenue range of 10 to 25 million dollars and recent funding of 2.5 million dollars, there is room for strategic partnerships or investments to scale up research, expand product lines, or accelerate commercialization efforts, creating new sales channels.

Ethical and Therapeutic Appeal ISCO’s focus on ethical, embryo-free stem cell technologies aligns with increasing market demand for safe and ethically sourced regenerative treatments, opening opportunities to license or develop therapies targeting eye, nervous system, and liver diseases for adoption by clinics and healthcare providers.

International Stem Cell Corporation's Email Address Formats

International Stem Cell Corporation uses at least 1 format(s):

International Stem Cell Corporation Email Formats	Example	Percentage
FLast@intlstemcell.com	JDoe@intlstemcell.com	46%
FirstL@intlstemcell.com	JohnD@intlstemcell.com	6%
First.Last@intlstemcell.com	John.Doe@intlstemcell.com	2%
FLast@intlstemcell.com	JDoe@intlstemcell.com	46%

International Stem Cell Corporation Email Formats

Example

Percentage

FLast@intlstemcell.com

JDoe@intlstemcell.com

46%

FirstL@intlstemcell.com

JohnD@intlstemcell.com

First.Last@intlstemcell.com

John.Doe@intlstemcell.com

FLast@intlstemcell.com

JDoe@intlstemcell.com

46%

Frequently Asked Questions

What is International Stem Cell Corporation's phone number?

You can contact International Stem Cell Corporation's main corporate office by phone at

+1-760-940-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is International Stem Cell Corporation's official website and social media links?

International Stem Cell Corporation's official website is intlstemcell.com and has social profiles on LinkedIn Crunchbase.

What is International Stem Cell Corporation's SIC code NAICS code?

International Stem Cell Corporation's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does International Stem Cell Corporation have currently?

As of December 2025, International Stem Cell Corporation has approximately 28 employees across 3 continents, including North AmericaAfricaAsia. Key team members include Vice Chairman Of The Board: S. B.Project Scientist: I. G.Assistant Scientist: M. P.. Explore International Stem Cell Corporation's employee directory with LeadIQ.

What industry does International Stem Cell Corporation belong to?

International Stem Cell Corporation operates in the Biotechnology Research industry.

What is International Stem Cell Corporation's email format?

International Stem Cell Corporation's email format typically follows the pattern of FLast@intlstemcell.com. Find more International Stem Cell Corporation email formats with LeadIQ.

How much funding has International Stem Cell Corporation raised to date?

As of December 2025, International Stem Cell Corporation has raised $2.5M in funding. The last funding round occurred on Oct 23, 2014 for $2.5M.

International Stem Cell Corporation

Biotechnology ResearchCalifornia, United States11-50 Employees

International Stem Cell Corporation (OTCBB:ISCO) develops a powerful new stem cell technology called “parthenogenesis” that promises to significantly advance the field of regenerative medicine by addressing the significant problem of immune-rejection. 

Parthenogenesis utilizes unfertilized human eggs to create “parthenogenetic” stem cells (hpSC) that can be “immune-matched” to millions of persons of differing sexes and racial backgrounds. A relatively small number of hpSC lines could provide sufficient immune-matched cells to cover large parts of the world’s population. ISCO plans to create a bank of these valuable hpSC lines (UniStemCell™) to serve all populations across the world. 

Human parthenogenetic stem cells have great therapeutic potential, yet do not require viable human embryos, thus avoiding ethical issues. ISCO’s scientists are focused on using hpSC to treat severe diseases of the eye, the nervous system and the liver where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells. 

ISCO advances and operates three businesses: Lifeline Cell Technology, Lifeline Skin Care and Universal Stem Cell Bank.

Insights

Similar companies to International Stem Cell Corporation

Lineage Cell Therapeutics

DiscGenics

Athersys

Brainstorm Cell Therapeutics